An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...
A team from Atrogi AB has reported the activity of ATR-127, a novel dual adrenergic agonist targeting β2- and β3-adrenoceptors (ARs), for the potential treatment of steatohepatitis, obesity and ...
STOCKHOLM, June 23, 2025 /PRNewswire/ -- Atrogi AB, a clinical-stage biotechnology company pioneering muscle-targeted therapies, today announces the publication of a landmark study in the prestigious ...
Prognostic value of circulating tumor DNA fraction (TF) for patients with metastatic renal cell carcinoma (mRCC). Effect of cytoreductive nephrectomy on the efficacy of immunotherapy in metastatic ...
The popularity of GLP-1-based drugs is testament to the importance of a drug that increases fat burning and lowers blood sugar. Now, a drug—taken in the form of a tablet—offers the outcome of ...
The repair of skin following injury is orchestrated by a complex interplay of inflammatory signals, cell migration and vascular remodelling. Among the key regulators are catecholamines—adrenaline and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results